256: Low-dose aspirin influences early pregnancy placentation in IVF /ICSI patients: Evidenced by a distinct maternal serum proteome profile

Abstract

PATIENTS: EVIDENCED BY A DISTINCT MATERNAL SERUM PROTEOME PROFILE MERVI HAAPSAMO, JUHA RASANEN, MICHAEL GRAVETT, SRINIVASA NAGALLA, University of Oulu, Obstetrics and Gynecology, Oulu, Finland, Oregon Health Sciences University, Obstetrics and Gynecology, Portland, Oregon, University of Washington, Obstetrics and Gynecology, Seattle, Washington, Proteogenix, Inc., Beaverton, Oregon OBJECTIVE: To investigate whether low-dose aspirin therapy when started prior to pregnancy affects maternal serum proteome profile reflecting placentation in the first trimester of pregnancy. STUDY DESIGN: Thirty pregnant women who had undergone IVF/ICSI and had been randomized to receive 100 mg aspirin (n 15) or placebo (n 15) daily starting on the first day of controlled ovarian hyperstimulation were included in this study. Maternal blood sample was taken at 10-13 weeks gestation for proteome analysis. Sera were processed to remove high-abundance proteins using immunoaffinity columns. Total serum protein from control, aspirin treated groups were labeled with Cy2, Cy3 and Cy5 fluorescent dyes and analyzed using multiplex 2-dimensional gel electrophoresis (2D-DIGE). Image analysis and spot quantification was performed using Phoretix software. Protein identification was performed utilizing liquid chromatography tandem mass spectrometry (LC-MS/MS) and MALDI-TOF-MS. RESULTS: Gestational age at delivery or perinatal outcome parameters did not differ between the groups. 2D-DIGE analysis of the serum proteome identified a distinct differential expression pattern between placebo and aspirin groups. Analysis of 176 spots by MALDI-TOF-MS and LC-MS/MS identified 62 unique proteins. Potential proteins influencing various pathways in the placentation process included extra-cellular matrix proteins, cytoskeletal proteins, apolipoproteins, complement proteins and transport proteins. CONCLUSION: Maternal serum proteome profiling suggests that low-dose aspirin therapy started prior to pregnancy could significantly influence placentation and pregnancy outcome.